Skip to main content

Does Biktarvy increase cholesterol?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Aug 19, 2025.

Official Answer by Drugs.com

Yes, Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) can increase cholesterol levels but this does not appear to be a frequent or serious side effect. Elevated LDL cholesterol (greater than 190 mg/dL) has been reported in 2% to 3% of patients (2 to 3 out of every 100 patients) taking Biktarvy in a clinical trial conducted by the manufacturer.

LDL (low density lipoprotein), sometimes called “bad” cholesterol, can increase your risk for heart disease, heart attack or stroke if left unchecked. Results can differ between patients, and cholesterol levels can increase due to age or other factors. It is important that you discuss your overall health with your doctor and determine if regular blood tests are needed to check your cholesterol levels.

Studies

Tenofovir alafenamide (TAF), as a component of Biktarvy, has been linked with slight increases in LDL cholesterol. However, research suggests the risk may be modest. Tenofovir disoproxil fumarate (TDF) has been linked with a lowering of lipids, but the clinical significance of this finding is also not known.

In a randomized, clinical study of TAF in patients new to antiretroviral treatment, levels of LDL ("bad") cholesterol, HDL (“good”) cholesterol, and triglycerides were elevated compared to tenofovir disoproxil fumarate (TDF). However, the total cholesterol to high-density lipoprotein ratio was unchanged for both, so the overall clinical impact is unknown, but there may be little difference.

Low-density lipoprotein (LDL) cholesterol elevations were more common in the group that received TAF compared to those receiving TDF (9% vs. 3%); however the absolute increase in LDL cholesterol (17 mg/dL vs. 11 mg/dL) was not significant (P=0.11).

At week 48, no differences in total cholesterol (P=0.54) or LDL cholesterol (P=0.37) were seen when patients were analyzed using the National Cholesterol Education Program (NCEP ATPIII) Adult Treatment Panel classification system, and no differences were seen in triglyceride changes.

Biktarvy has also been reported to elevated LDL cholesterol in further randomized, controlled studies in 2% to 5% of participants. TAF is found in other combination medications used for HIV treatment or prevention.

What other side effects occur with Biktarvy?

Overall, Biktarvy is well-tolerated by most patients. In three-year studies completed by the manufacturer, only 1% of adults who received Biktavry as their first HIV treatment stopped the medicine due to side effects.

The most common side effects with Biktarvy include: diarrhea (in 6% of patients), nausea (6%), and headache (5%).

Biktarvy may also worsen hepatitis B (HBV) infection. If you have both HIV-1 and HBV and stop taking this treatment, your HBV may suddenly worsen. Do not stop taking Biktarvy without first talking to your health care provider, as they will need to monitor your health.

Other serious side effects for Biktarvy include:

These are not all the side effects reported with Biktary. Tell your doctor immediately if any new or worsening side effects occur during treatment. You can review a full list of side effects here.

Related questions

How is Biktarvy used in HIV treatment?

Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide, often abbreviated BIC/FTC/TAF), was first approved in 2018 to treat human immunodeficiency virus (HIV). Biktarvy is for use in adults and children who weigh at least 14 kg (31 lb). The manufacturer is Gilead Sciences.

Biktarvy is not a cure for HIV or AIDS, but can help many people achieve and maintain undetectable viral loads.

Biktarvy is taken as once-daily, single oral tablet regimen:

Key Takeaways

Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) can increase cholesterol levels due to the tenofovir alafenamide (TAF) component, but this does not appear to be a frequent or significant side effect.

Elevated LDL ("bad") cholesterol (greater than 190 mg/dL) has been reported in 2% to 3% of patients (2 to 3 out of every 100 patients) taking Biktarvy in one clinical trial.

Biktarvy is well-tolerated by most patients. The most common side effects with Biktary may include diarrhea (in 6% of patients), nausea (6%) and headache (5%).

This is not all the information you need to know about Biktarvy for safe and effective use and does not replace your healthcare provider's directions. Review the full product information and discuss this information and any questions with your health care provider.

References
  • Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67(1):52-58. doi:10.1097/QAI.0000000000000225
  • Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016 Apr;3(4):e158-65.
  • Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection [correction Drugs. 2019 Mar 22] Drugs. 2018;78(17):1817-1828. doi:10.1007/s40265-018-1010-7
  • Biktarvy [package insert]. Foster City, CA. Gilead. 7/2025. Accessed Aug 19, 2025 at https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf

Read next

Do you have to take Biktarvy forever?

Biktarvy antiretroviral therapy (ART) is taken indefinitely for HIV-1 infection as it is a complete regimen for long-term treatment. Stopping ART can increase blood levels of the HIV virus, lead to resistance, increase your risk for HIV infections and complications and increase the chance that you may transmit the infection to others.

Continue reading

Can I drink alcohol while taking Biktarvy?

There is not a specific warning in the product label against alcohol (ethanol) consumption with Biktarvy, a medication used for HIV treatment. But drinking too much alcohol can damage your liver. Ask your doctor if it is safe and how much alcohol you can drink while taking Biktarvy.

Continue reading

Is Biktarvy covered by insurance?

Most commercial and government health insurance plans in the U.S. cover some portion of the cost for Biktarvy. Typically a person taking Biktarvy pays between $0 and $5 per month. A co-pay card program for Biktarvy offers up to $7,200 in cost-sharing assistance per year with no monthly limit.

Continue reading

See also:

Related medical questions

Drug information

Related support groups